Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders

Bibliography

• Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997;37:205-37
   PubMed Web of Science ®Google Scholar
• Nakanishi S, Nakajima Y, Masu M, Glutamate receptors: brain function and signal transduction. Brain Res Brain Res Rev 1998;26:230-5
   PubMed Web of Science ®Google Scholar
• Schoepp DD, Jane DE, Monn JA. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999;38:1431-76
   PubMed Web of Science ®Google Scholar
• Valenti O, Marino MJ, Wittmann M, Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. J Neurosci 2003;23:7218-26
   PubMed Web of Science ®Google Scholar
• Marino MJ, Hess JF, Liverton N. Targeting the metabotropic glutamate receptor mGluR4 for the treatment of diseases of the central nervous system. Curr Top Med Chem 2005;5:885-95
   PubMed Web of Science ®Google Scholar
• Lavreysen H, Dautzenberg FM. Therapeutic potential of group III metabotropic glutamate receptors. Curr Med Chem 2008;15:671-84
   PubMed Web of Science ®Google Scholar
• Johansen PA, Chase LA, Sinor AD, Type 4a metabotropic glutamate receptor: identification of new potent agonists and differentiation from the L-(+)-2-Amino-4-phosphonobutanoic acid-sensitive receptor in the lateral perforant pathway in rats. Mol Pharmacol 1995;48:140-9
   PubMed Web of Science ®Google Scholar
• Trombley PQ, Westbrook GL. L-AP4 inhibits calcium currents and synaptic transmission via a G-protein-coupled glutamate receptor. J Neurosci 1992;12:2043-50
   PubMed Web of Science ®Google Scholar
• MacInnes N, Messenger MJ, Duty S. Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat. Br J Pharmacol 2004;141:15-22
   PubMed Web of Science ®Google Scholar
• Selvam C, Goudet C, Oueslati N, L-(+)-2-Amino-4-thiophosphonobutyric acid (L-thioAP4), a new potent agonist of group III metabotropic glutamate receptors: increased distal acidity affords enhanced potency. J Med Chem 2007;50:4656-64
   PubMed Web of Science ®Google Scholar
• Acher FC, Tellier FJ, Azerad R, Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: new tools to discriminate between metabotropic glutamate receptor subtypes. J Med Chem 1997;40:3119-29
   PubMed Web of Science ®Google Scholar
• Institut National des Sciences Appliquees de Rouen (INSA). Preparation of fluorinated cyclopropane analogs of glutamic acid as mGluR4 modulators useful in the treatment of neurological diseases. WO2011009947; 2011
   Google Scholar
• Sibille P, Lopez S, Brabet I, Synthesis and biological evaluation of 1-Amino-2-phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists. J Med Chem 2007;50:3585-95
   PubMed Web of Science ®Google Scholar
• Triballeau N, Acher F, Brabet I, Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. J Med Chem 2005;48:2534-47
   PubMed Web of Science ®Google Scholar
• Selvam C, Oueslati N, Lemasson IA, A virtual screening hit reveals new possibilities for developing group III metabotropic glutamate receptor agonists. J Med Chem 2010;53:2797-813
   PubMed Web of Science ®Google Scholar
• Centre National De La Recherche Scientifique. Preparation of hypophosphorous acid derivatives, particularly substituted hypophosphorous acid-containing glycine derivatives, as agonists and antagonists of metabotropic glutamate receptors, especially mGluR4. WO2007052169; 2007
   Google Scholar
• Hampson DR, Huang XP, Pekhletski R, Probing the ligand-binding domain of the mGluR4 subtype of metabotropic glutamate receptor. J Biol Chem 1999;274:33488-95
   PubMed Web of Science ®Google Scholar
• Acher FC, Selvam C, Pin JP, A critical pocket close to the glutamate binding site of mGlu receptors opens new possibilities for agonist design. Neuropharmacology 2011;60:102-7
   PubMed Web of Science ®Google Scholar
• Goudet C, Vilar B, Courtiol T, A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential. FASEB J 2012; published online on January 5, 2012; doi: 10.1096/fj.11-195941.
   PubMed Web of Science ®Google Scholar
• Cuomo D, Martella G, Barabino E, Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment. J Neurochem 2009;109:1096-105
   PubMed Web of Science ®Google Scholar
• Burford NT, Watson J, Bertekap R, Alt A. Strategies for the identification of allosteric modulators of G-protein-coupled receptors. Biochem Pharmacol 2011;81:691-702
   PubMed Web of Science ®Google Scholar
• Bridges TM, Lindsley CW. G-Protein-Coupled receptors: from classical modes of modulation to allosteric mechanisms. Chem Biol 2008;19(3):530-41
   Google Scholar
• Rocheville M, Garland SL. An industrial perspective on positive allosteric modulation as a means to discover safe and selective drugs. Drug Discov Today 2010;7:e87-94
   Google Scholar
• Maj M, Bruno V, Dragic Z, (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology 2003;45:895-906
   PubMed Web of Science ®Google Scholar
• Marino MJ, Williams DL Jr, O'Brien JA, Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci USA 2003;100:13668-73
   PubMed Web of Science ®Google Scholar
• Williams R, Zhou Y, Niswender CM, Re-exploration of the PHCCC scaffold: discovery of improved positive allosteric modulators of mGluR4. ACS Chem Neurosci 2010;1:411-19
   PubMed Web of Science ®Google Scholar
• Domain Therapeutics, Prestwick Chemical. Preparation of novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors. WO2011051478; 2011
   Google Scholar
• Niswender CM, Johnson KA, Weaver CD, Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol 2008;74:1345-58
   PubMed Web of Science ®Google Scholar
• Doller D, Hong SP, Uberti MA, LuAF219934, a brain penetrant mGluR4 receptor positive allosteric modulator tool compound [Poster 655.28]. Society for Neuroscience Meeting; San Diego; 2011
   Google Scholar
• Christov C, Gonzalez-Bulnes P, Malhaire F, Integrated synthetic, pharmacological, and computational investigation of cis-2-(3,5-dichlorophenylcarbamoyl)cyclohexanecarboxylic acid enantiomers as positive allosteric modulators of metabotropic glutamate receptor subtype 4. ChemMedChem 2011;6:131-40
   PubMed Web of Science ®Google Scholar
• East SP, Bamford S, Dietz MG, An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction. Bioorg Med Chem Lett 2010;20:4901-5
   PubMed Web of Science ®Google Scholar
• Mathiesen JP, Svenden N, Braumer-Osborne H, Positive allosteric modulation of human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol 2003;138:1026-30
   PubMed Web of Science ®Google Scholar
• Robichaud AJ, Engers DW, Lindsley CW, Hopkins CR. Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics. ACS Chem Neurosci 2011;2:433-49
   PubMed Web of Science ®Google Scholar
• Reynolds IJ. Metabotropic glutamate receptors as therapeutic targets in Parkinson's Disease. 6th International Meeting on Metabotropic Glutamate Receptors; Taormina; 2008
   Google Scholar
• Merck & Co. Preparation of phthalimidephenylpyridinecarboxamide derivatives for use as metabotropic glutamate R4 modulators. WO2010033349; 2010
   Google Scholar
• Merck & Co. Sulfonamide derivatives as mGluR4 receptor ligands. WO2010033350; 2010
   Google Scholar
• Addex Pharma S.A. Preparation of amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors. WO2009010454; 2009
   Google Scholar
• Engers DW, Niswender CM, Weaver CD, Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). J Med Chem 2009;52:4115-18
   PubMed Web of Science ®Google Scholar
• Jones CK, Bubser M, Thompson AD, The mGlu4 positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine A2A antagonist in preclinical rodent models of Parkinson's disease. J Pharmacol Exp Ther 2012;340:404-21
   PubMed Web of Science ®Google Scholar
• Engers DW, Field JR, Le U, Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in rats. J Med Chem 2011;54:1106-10
   PubMed Web of Science ®Google Scholar
• Engers DW, Gentry PR, Williams R, Synthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS). Bioorg Med Chem Lett 2010;20:5175-8
   PubMed Web of Science ®Google Scholar
• Jones CK, Engers DW, Thompson AD, Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu4) with oral efficacy in an antiparkinsonian animal model. J Med Chem 2011;54:7639-47
   PubMed Web of Science ®Google Scholar
• Vanderbilt University. Imidazolidinone derivatives and related compounds as mGluR4 allosteric potentiators and their preparation, compositions, and methods of treating neurological dysfunction. WO2011029104; 2011
   Google Scholar
• Vanderbilt University. Metabotropic glutamate receptor subtype 4 allosteric potentiator compositions and methods of treating neurological dysfunction. WO2011050316; 2011
   Google Scholar
• Vanderbilt University. Heterocyclic sulfone metabotropic glutamate receptor subtype 4 allosteric potentiators and compositions, and methods of treating neurological dysfunction. WO2011143466; 2011
   Google Scholar
• Vanderbilt University. Aryl and heteroaryl sulfones as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction. WO2011057208; 2011
   Google Scholar
• Vanderbilt University. Substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mGluR4 potentiators. WO2011011722; 2011
   Google Scholar
• Vanderbilt University. Benzisoxazoles and azabenzisoxazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction. WO2011100614; 2011
   Google Scholar
• Celanire S, Bolea C, Bruckner S, Discovery and characterization of novel metabotropic glutamate receptor 4 (mGluR4) allosteric potentiators [abstract 24]. Taormina: 7th International Meeting on Metabotropic Glutamate Receptors (October 2-7, 2011). Curr Neuropharmacol 2011;9(Suppl 1):8
   PubMedGoogle Scholar
• Addex Pharma S.A. Preparation of novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors. WO2009010455; 2009
   Google Scholar
• Addex Pharma S.A. Novel thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors and preparation. WO2010079239; 2010
   Google Scholar
• Addex Pharma S.A. Preparation of 4-amino-thiazoles and 3-amino-1,2,4-thiadiazoles and their use as allosteric modulators of metabotropic glutamate receptors. WO2011086163; 2011
   Google Scholar
• Addex Pharma S.A. Novel pyrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors and their preparation. WO2011010222; 2011
   Google Scholar
• Addex Pharma S.A. Preparation of heteroaryldihydrothiazoloindazoleamine derivatives and analogs as metabotropic glutamate receptors modulators. WO2010079238; 2010
   Google Scholar
• Hong SP, Liu KG, Ma G, Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem 2011;54:5070-81
   PubMed Web of Science ®Google Scholar
• Drolet RE, Tugusheva K, Liverton N, Binding property characterization of a novel mGluR4 positive allosteric modulator [Poster 553.12]. Society for Neuroscience meeting; Washington; 2011
   Google Scholar
• Utley T, Haddenham D, Salovich JM, Synthesis and SAR of a novel metabotropic glutamate receptor 4 (mGlu4) antagonist: unexpected 'molecular switch' from a closely related mGlu4 positive allosteric modulator. Bioorg Med Chem Lett 2011;21:6955-9
   PubMed Web of Science ®Google Scholar
• Marino MJ, Awad H, Poisik O, Localization and physiological roles of metabotropic glutamate receptors in the direct and indirect pathways of the basal ganglia. Amino Acids 2002;23:185-91
   PubMed Web of Science ®Google Scholar
• Bradley SR, Standaert DG, Rhodes KJ, Immunohistochemical Localization of Subtype 4a metabotropic glutamate receptors in the rat and mouse Basal Ganglia. J Comp Neurol 1999;407:33-46
   PubMed Web of Science ®Google Scholar
• Meissner WG, Frasier M, Gasser T, Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011;10:377-93
   PubMed Web of Science ®Google Scholar
• Smith Y, Wichmann T, Factor SA, Delong MR. Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology 2011;37:213-46
   PubMed Web of Science ®Google Scholar
• Salamone JD. Facing Dyskinesia in Parkinson's disease: nondopaminergic approaches. Drugs Future 2010;35:567-73
   Web of Science ®Google Scholar
• Lindsley CW, Niswender CM, Engers DW, Hopkins CR. Recent progress in the development of mGluR4 positive allosteric modulators for the treatment of Parkinson's disease. Curr Top Med Chem 2009;9:949-63
   PubMed Web of Science ®Google Scholar
• Duty S. Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease. Br J Pharmacol 2010;161:271-87
   PubMed Web of Science ®Google Scholar
• Sibille P, Lopez S, Brabet I, Synthesis and biological evaluation of 1-amino-2-phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists. J Med Chem 2007;50:3585-95
   PubMed Web of Science ®Google Scholar
• Konieczny J, Wardas J, Kuter K, The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats. Neuroscience 2007;145:611-20
   PubMed Web of Science ®Google Scholar
• Lopez S, Turle-Lorenzo N, Acher F, Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. J Neurosci 2007;27:6701-11
   PubMed Web of Science ®Google Scholar
• Conn PJ, Battaglia G, Marino MJ, Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 2005;6:787-98
   PubMed Web of Science ®Google Scholar
• Beurrier C, Lopez S, Revy D, Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J 2009;23:3619-28
   PubMed Web of Science ®Google Scholar
• Deltheil T, Turle-Lorenzo N, Amalric M. Orthosteric group III mGlu receptor agonist for Parkinson's disease treatment: symptomatic and neurochemical action on pallidal synaptic transmission [abstract 40]. Taormina: 7th International Meeting on Metabotropic Glutamate Receptors (October 2-7, 2011). Curr Neuropharmacol 2011;9(Suppl 1):8
   PubMedGoogle Scholar
• Reynolds IJ. Novel mGluR4 Positive Allosteric Modulators for Parkinson's Disease. World Pharma Congress - Targeting Parkinson's Disease; Philadelphia: 2011
   Google Scholar
• Campo B. Novel metabotropic glutamate receptor 4 (mGluR4) allosteric potentiators for the treatment of Parkinson's disease and anxiety [abstract 22]. Taormina: 7th International Meeting on Metabotropic Glutamate Receptors (October 2-7, 2011). Curr Neuropharmacol 2011;9(Suppl 1):8
   PubMedGoogle Scholar
• Bennouar KE, Uberti MA, Melon C, Synergy between L-DOPA and a novel positive metabotropic glutamate receptor 4: implication for Parkinson's disease treatment and dyskinesia. Neuropharmacology 2012; submitted
   PubMed Web of Science ®Google Scholar
• Niswender C. The Development of Positive Allosteric Modulators of mGluR4 for the Treatment of Parkinson's Disease. Allosteric Modulator Drug Discovery Congress; San Diego: 2010
   Google Scholar
• Shanker YG. Identification and Characterization of Allosteric Modulators of mGluR4 for the Treatment of Parkinson's Disease. Discovery on Target meeting - Targeting Diverse Pathways for Tomorrow's Therapeutics; Boston: 2010
   Google Scholar
• Valenti O, Mannaioni G, Seabrook GR, Group III metabotropic glutamate-receptor-mediated modulation of excitatory transmission in rodent substantia nigra pars compacta dopamine neurons. J Pharmacol Exp Ther 2005;313:1296-304
   PubMed Web of Science ®Google Scholar
• Vernon AC, Zbarsky V, Datla KP, Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4-phosphonobutryic acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J Pharmacol Exp Ther 2007;320:397-409
   PubMed Web of Science ®Google Scholar
• Vernon AC, Palmer S, Datla KP, Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Eur J Neurosci 2005;22:1799-806
   PubMed Web of Science ®Google Scholar
• Battaglia G, Busceti CL, Molinaro G, Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine. J Neurosci 2006;26:7222-9
   PubMed Web of Science ®Google Scholar
• Prediger RD, Matheus FC, Schwarzbold ML, Anxiety in Parkinson's disease: a critical review of experimental and clinical studies. Neuropharmacology 2012;62:115-24
   PubMed Web of Science ®Google Scholar
• Palucha A, Pilc A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther 2007;115:116-47
   PubMed Web of Science ®Google Scholar
• Stachowicz K, Klodzinska A, Palucha-Poniewiera A, The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems. Neuropharmacology 2009;57:227-34
   PubMed Web of Science ®Google Scholar
• Wieronska JM, Stachowicz K, Palucha-Poniewiera A, Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems. Neuropharmacology 2010;59:627-34
   PubMed Web of Science ®Google Scholar
• Campo B. Validating the Role of mGluR4 Receptors in the Physiopathology of Anxiety using a Selective mGluR4 Positive Allosteric Modulator. Allosteric Modulator Drug Discovery Congress; San Diego: 2010
   Google Scholar
• Klak K, Palucha A, Branski P, Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats. Amino Acids 2007;32:169-72
   PubMed Web of Science ®Google Scholar
• Palucha A, Tatarczynska E, Branski P, Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology 2004;46:151-9
   PubMed Web of Science ®Google Scholar
• Scrivo R, Vasile M, Bartosiewicz I, Valesini G. Inflammation as "common soil" of the multifactorial diseases. Autoimmun Rev 2011;10:369-74
   PubMed Web of Science ®Google Scholar
• Nicoletti F, Bruno V, Copani A, Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci 1996;19:267-71
   PubMed Web of Science ®Google Scholar
• Taylor DL, Diemel LT, Pocock JM. Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity. J Neurosci 2003;23:2150-60
   PubMed Web of Science ®Google Scholar
• Fallarino F, Volpi C, Fazio F, Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat Med 2010;16:897-902
   PubMed Web of Science ®Google Scholar
• Neugebauer V. Glutamate receptor ligands. Handb Exp Pharmacol 2007;177:217-49
   PubMedGoogle Scholar
• Goudet C, Magnaghi V, Landry M, Metabotropic receptors for glutamate and GABA in pain. Brain Res Rev 2009;60:43-56
   PubMed Web of Science ®Google Scholar
• Goudet C, Chapuy E, Allaoui A, Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain. Pain 2008;137:112-24
   PubMed Web of Science ®Google Scholar
• Wang H, Jiang W, Yang R, Li Y. Spinal metabotropic glutamate receptor 4 is involved in neuropathic pain. Neuroreport 2011;22:244-8
   PubMed Web of Science ®Google Scholar
• Kinon BJ. Clinical aspects of modulation of glutamatergic mechanisms in the treatment of Schizophrenia. Drugs Future 2010;35:557-66
   Web of Science ®Google Scholar
• Palucha-Poniewiera A, Klodzinska A, Stachowicz K, Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents. Neuropharmacology 2008;55:517-24
   PubMed Web of Science ®Google Scholar
• Wieronska JM, Stachowicz K, Acher F, Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia. Psychopharmacology 2011; published on line 28 September 2011; doi: 10.1007/s00213-011-2502-2
   PubMed Web of Science ®Google Scholar
• Muhle H, von SS, Gaus V, Role of GRM4 in idiopathic generalized epilepsies analysed by genetic association and sequence analysis. Epilepsy Res 2010;89:319-26
   PubMed Web of Science ®Google Scholar
• Ngomba RT, Ferraguti F, Badura A, Positive allosteric modulation of metabotropic glutamate 4 (mGlu4) receptors enhances spontaneous and evoked absence seizures. Neuropharmacology 2008;54:344-54
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Kaida Y, Fukuhara S, Participation of metabotropic glutamate receptors in pentetrazol-induced kindled seizure. Epilepsia 2011;52:140-50
   PubMed Web of Science ®Google Scholar
• Moyanova SG, Mastroiacovo F, Kortenska LV, Protective role for type 4 metabotropic glutamate receptors against ischemic brain damage. J Cereb Blood Flow Metab 2011;31:1107-18
   PubMed Web of Science ®Google Scholar
• de Groot J, Sontheimer H. Glutamate and the biology of gliomas. Glia 2011;59:1181-9
   PubMed Web of Science ®Google Scholar
• Brocke KS, Staufner C, Luksch H, Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol Ther 2010;9:455-68
   PubMed Web of Science ®Google Scholar
• Pissimissis N, Papageorgiou E, Lembessis P, The glutamatergic system expression in human PC-3 and LNCaP prostate cancer cells. Anticancer Res 2009;29:371-7
   PubMed Web of Science ®Google Scholar
• Iacovelli L, Arcella A, Battaglia G, Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas. J Neurosci 2006;26:8388-97
   PubMed Web of Science ®Google Scholar
• Uehara S, Muroyama A, Echigo N, Metabotropic glutamate receptor type 4 is involved in autoinhibitory cascade for glucagon secretion by alpha-cells of islet of Langerhans. Diabetes 2004;53:998-1006
   PubMed Web of Science ®Google Scholar
• Tong Q, Ouedraogo R. Kirchgessner Al. Localization and function of group III metabotropic glutamate receptors in rat pancreatic islets. Am J Physiol Endocrinol Metab 2002;282(6):E1324-33
   PubMed Web of Science ®Google Scholar
• Tanabe Y, Masu M, Ishii T, A Family of metabotropic glutamate receptors. Neuron 1992;8:169-79
   PubMed Web of Science ®Google Scholar
• Flor PJ, Lukic S, Ruegg D, Molecular cloning, functional expression and pharmacological characterization of the human metabotropic glutamate receptor type 4. Neuropharmacology 1995;34:149-55
   PubMed Web of Science ®Google Scholar
• Marshall FH. Is the GABA B heterodimer a good drug target? J Mol Neurosci 2005;26:169-76
   PubMed Web of Science ®Google Scholar
• Wichmann T, DeLong MR. Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol 1996;6:751-8
   PubMed Web of Science ®Google Scholar
• Pekhletski R, Gerlai R, Overstreet LS, Impaired cerebellar synaptic plasticity and motor performance in mice lacking the mGluR4 subtype of metabotropic glutamate receptor. J Neurosci 1996;16:6364-73
   PubMed Web of Science ®Google Scholar
• Makoff A, Lelchuk R, Oxer M, Molecular characterization and localization of human metabotropic glutamate receptor type 4. Brain Res Mol Brain Res 1996;37:239-48
   PubMedGoogle Scholar